Drugs / AC682
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05489679 | Oct 2022 → Sep 2023 | breast cancer | Accutar Biotechnology Inc | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05080842 | Nov 2021 → Apr 2024 | breast cancer | Accutar Biotechnology Inc | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AC682 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05489679 ↗ |
| Action | Inhibit | “estrogen receptor degrader” NCT05489679 ↗ |
| Route | Oral | “Participants will receive AC682 by mouth daily in 28-day cycles.” NCT05080842 ↗ |